The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users

Biomedicine and Pharmacotherapy

Volumn 67, Issue 6, 2013, Pages 517-520

  Bojovic, K ^a   Simonovic, J ^a   Katanic, N ^b   Milosevic, I ^a   Pesic, I ^c   Delic, D ^a   Svirtlih, N ^a   Jevtovic, D J ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF PRI TINA   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Antiviral therapy; Hepatitis C; Intravenous drug users

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL THERAPY; HEPATITIS C; INTRAVENOUS DRUG USERS;

ADULT; ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84880948351     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.010     Document Type: Article

References (17)

1. Abdel-Waha M.F., Zakaria S., Kamel M., et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994, 51:563-567.
2. McMahon B., Lavanchy D. Worlwide prevalence and prevention of hepatitis C. Hepatitis C 2000, 185-200. Academic Press, London. J.H. Hoofnagle, T.J. Liang (Eds.).
3. Alter M.J., et al. Epidemiology of hepatitis C. Hepatitis C 2000, 169-182. Academic Press, London. J.H. Hoofnagle, T.J. Liang (Eds.).
4. Hellard M., Sacks/Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. CID 2009, 49:569-572.
5. Jafferbhou H., Miller M.H., Dunbar J.K., tait S., Mcleod S., Dillon J.F. Intravenous drug use in HCV infection. J Viral Hepat 2012, 19(2):112-119.
6. Ružić M., Fabri M., Klašnja B., PoborM, Švarc D., Jovelić A., et al. Efikasnost kombinovane antivirusne terapije pegilovanim interferonom alfa 2a i ribavirinom u lečenju hroničnog C virusnog hepatitisa kod intravenskihzavisnika od opijata. Srp Arh 2010, 138(1-2):43-49.
7. Kurelac I., Papic N., Sakoman S., Orban M., Dusek D., Coric M., et al. Intravenous drug users can achieve a high sustained virological response rate: experience from Croatian reference center for viral hepatitis. Hepat Mon 2011, 11(12):986-992.
8. Sulkowski M.S., Thomas D.L. Epidemiology and natural history of hepatitis C virus infection drug users: implications for treatment. Clin Infect Dis 2005, 40(Suppl. 5):263-269.
9. Schaefer M., Schmidt F., Folwaczny C., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37(2):443-451.
10. Scheafer M., Heinz A., Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 2004, 99(9):1167-1175.
11. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40:120-124.
12. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa 2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
13. Freid M.W., Shiffman M.L., Rajnder R.K., et al. Peginterferon Alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
14. Dalgard O., Bjoro K., Hellum K., et al. Treatment of chronic hepatitis C in injecting drug users: 5 years follow-up. Eur Addict Res 2002, 8:45-49.
15. Backmund M., Mayer K., Edlin BR Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004, 39:1540-1543.
16. Hollander J.G., Rijnders B.J., van Doornum G.J., van der Ende M.E. Sexually transmitted reinfection with a new hepatitis C genotype during pegilated interferon and ribavirin therapy. AIDS 2005, 19:639-640.
17. Von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha 2a (4okD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.